Literature DB >> 25374164

Research progress in applying proteomics technology to explore early diagnosis biomarkers of breast cancer, lung cancer and ovarian cancer.

Lu Luo1, Li-You Dong, Qi-Gui Yan, San-Jie Cao, Xin-Tian Wen, Yong Huang, Xiao-Bo Huang, Rui Wu, Xiao-Ping Ma.   

Abstract

According to the China tumor registry 2013 annual report , breast cancer, lung cancer, and ovarian cancer are three common cancers in China nowadays, with high mortality due to the absence of early diagnosis technology. However, proteomics has been widespreadly implanted into every field of life science and medicine as an important part of post-genomics era research. The development of theory and technology in proteomics has provided new ideas and research fields for cancer research. Proteomics can be used not only for elucidating the mechanisms of carcinogenesis focussing on whole proteins of the tissue or cell, but also seeking the biomarkers for diagnosis and therapy of cancer. In this review, we introduce proteomics principles, covering current technology used in exploring early diagnosis biomarkers of breast cancer, lung cancer and ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25374164     DOI: 10.7314/apjcp.2014.15.20.8529

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

1.  Proteomic identification of alpha-2-HS-glycoprotein as a plasma biomarker of hypopharyngeal squamous cell carcinoma.

Authors:  Wen-Dong Tian; Jun-Zheng Li; Shui-Wang Hu; Xiao-Wei Peng; Gang Li; Xiong Liu; Huai-Hong Chen; Xia Xu; Xiang-Ping Li
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  FGB and FGG derived from plasma exosomes as potential biomarkers to distinguish benign from malignant pulmonary nodules.

Authors:  Muyu Kuang; Yizhou Peng; Xiaoting Tao; Zilang Zhou; Hengyu Mao; Lingdun Zhuge; Yihua Sun; Huibiao Zhang
Journal:  Clin Exp Med       Date:  2019-10-01       Impact factor: 3.984

Review 3.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

4.  MicroRNA-155 hallmarks promising accuracy for the diagnosis of various carcinomas: results from a meta-analysis.

Authors:  Chuancheng Wu; Qiuyan Liu; Baoying Liu
Journal:  Dis Markers       Date:  2015-03-30       Impact factor: 3.434

5.  MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance.

Authors:  Dong Lan; Xin Zhang; Rongquan He; Ruixue Tang; Ping Li; Qiancheng He; Gang Chen
Journal:  Eur J Med Res       Date:  2015-04-23       Impact factor: 2.175

6.  Simple and effective label-free electrochemical immunoassay for carbohydrate antigen 19-9 based on polythionine-Au composites as enhanced sensing signals for detecting different clinical samples.

Authors:  Zhengjun Huang; Zhouqian Jiang; Chengfei Zhao; Wendi Han; Liqing Lin; Ailin Liu; Shaohuang Weng; Xinhua Lin
Journal:  Int J Nanomedicine       Date:  2017-04-13

7.  eIF4E Overexpression Is Associated with Poor Prognoses of Ovarian Cancer.

Authors:  Jun Zheng; Xueqing Li; Chunyan Zhang; Yiqiang Zhang
Journal:  Anal Cell Pathol (Amst)       Date:  2020-12-12       Impact factor: 2.916

Review 8.  Optimizing the Detection of Circulating Markers to Aid in Early Lung Cancer Detection.

Authors:  Vasudha Murlidhar; Nithya Ramnath; Sunitha Nagrath; Rishindra M Reddy
Journal:  Cancers (Basel)       Date:  2016-06-28       Impact factor: 6.639

9.  Clinicopathological and Prognostic Role of STAT3/p-STAT3 in Breast Cancer Patients in China: A Meta-Analysis.

Authors:  Yang Li; Yue Wang; Zhixiang Shi; Jinghan Liu; Shuyun Zheng; Jinsong Yang; Yi Liu; Yuhua Yang; Feng Chang; Wenying Yu
Journal:  Sci Rep       Date:  2019-08-02       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.